Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Accumulated Depreciation & Amortization: 2010-2025

Historic Accumulated Depreciation & Amortization for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $83.3 million.

  • Myriad Genetics' Accumulated Depreciation & Amortization fell 28.99% to $83.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.8 million, marking a year-over-year decrease of 23.17%. This contributed to the annual value of $109.6 million for FY2024, which is 8.59% down from last year.
  • Per Myriad Genetics' latest filing, its Accumulated Depreciation & Amortization stood at $83.3 million for Q3 2025, which was up 4.91% from $79.4 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Accumulated Depreciation & Amortization high stood at $119.9 million for Q4 2023, and its period low was $79.4 million during Q2 2025.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $112.2 million (2023), whereas its average is $105.8 million.
  • Per our database at Business Quant, Myriad Genetics' Accumulated Depreciation & Amortization increased by 9.80% in 2023 and then plummeted by 31.02% in 2025.
  • Myriad Genetics' Accumulated Depreciation & Amortization (Quarterly) stood at $106.9 million in 2021, then grew by 2.15% to $109.2 million in 2022, then rose by 9.80% to $119.9 million in 2023, then declined by 8.59% to $109.6 million in 2024, then fell by 28.99% to $83.3 million in 2025.
  • Its last three reported values are $83.3 million in Q3 2025, $79.4 million for Q2 2025, and $83.5 million during Q1 2025.